CTD Holdings, Inc.: CTD Holdings to Institutionalize Niemann-Pick C Efforts

Published in Health and Fitness on Monday, June 8th 2009 at 5:15 GMT, Last Modified on 2009-06-08 05:16:54 by Market Wire
^{🞛 This publication is a summary or evaluation of another publication}

HIGH SPRINGS, FL--(Marketwire - June 8, 2009) - CTD Holdings, Inc. (OTCBB: [ CTDH ]) (FRANKFURT: CDJ) announces the creation of an Ameliorative Therapies department within its wholly owned subsidiary, CTD Inc. This department, through the use of existing staff and independent consultants, will oversee the collection, collation and analysis of data on the ameliorative uses of Cyclo™ coming from existing and new compassionate use trials around the world.

CTDH is currently applying for Trademark protection for Cyclo™, a new product line to be used exclusively for research and compassionate use in conjunction with dysfunctional cholesterol metabolism ailments and diseases. Currently, the product is being used under an FDA approved compassionate use treatment for Niemann-Pick C patients.

"The Addi and Cassi Hempel (see [ www.WebofHope.com ]) compassionate use trial with Cyclo™ has initiated worldwide contacts from physicians treating Niemann-Pick C patients in the US, India, Lebanon, Spain, Japan, and China. Additionally, the medical research community in the US and England, specializing in cholesterol metabolism, are ordering Trappsol® (CTD's branded CDs) radiolabelled Cyclo™," stated Mr. C.E. Strattan (Pres/CEO). "It appears that Cyclo™'s role in dysfunctional cholesterol metabolism has come to the attention of some very qualified medical research faculties."

Dysfunctional cholesterol metabolism has been implicated in the etiology of Adult and Childhood Alzheimer's, HIV Aids, Coronary Artery Disease, and Diabetes. "Creating the conduit for the efficient collection of the compassionate use data will expedite routine use of Cyclo™ in ameliorative scenarios," promises Mr. Strattan.

About CTD Holdings, Inc.

The company is the one-stop shop, business to business facilitator of commercial and research applications of cyclodextrins. With its branded Trappsol® and Aquaplex® product offerings, CTDH scientists coordinate the development of commercial products for use in the pharmaceuticals, foods, hazardous waste treatment, and cosmetics industries, just to name a few of the industries which endeavor to put non water-soluble ingredients into water-based formulations. More recently CTDH has worked, in an advisory capacity, on the benefits and application of Cyclodextrins as a treatment for Niemann Picks disease, a debilitating childhood disease often associated with Alzheimer's. CTDH was founded in 1990 as a Florida corporation and became a public company in 1994. Additional information on the Company can be found on the Company's website: [ www.cyclodex.com ]

This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH complies with the regulations and time lines mandated by the SEC in the filing of its financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc accepts no specific responsibility for updating such statements.

Publication Contributing Sources